Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial
- PMID: 29440149
- DOI: 10.1136/bmjspcare-2017-001440
Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial
Abstract
Cancer cachexia is a multifactorial syndrome characterised by an ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support alone. Cachexia has a high prevalence in cancer and a major impact on patient physical function, morbidity and mortality. Despite the consequences of cachexia, there is no licensed treatment for cachexia and no accepted standard of care. It has been argued that the multifactorial genesis of cachexia lends itself to therapeutic targeting through a multimodal treatment. Following a successful phase II trial, a phase III randomised controlled trial of a multimodal cachexia intervention is under way. Termed the MENAC trial (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia), this intervention is based on evidence to date and consists of non-steroidal anti-inflammatory drugs and eicosapentaenoic acid to reduce inflammation, a physical exercise programme using resistance and aerobic training to increase anabolism, as well as dietary counselling and oral nutritional supplements to promote energy and protein balance. Herein we describe the development of this trial.
Trial registration number: NCT02330926.
Keywords: cachexia; trial.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Combination therapy in cachexia.Ann Palliat Med. 2019 Jan;8(1):59-66. doi: 10.21037/apm.2018.08.05. Epub 2018 Aug 27. Ann Palliat Med. 2019. PMID: 30180745 Review.
-
Exercise for cancer cachexia in adults.Cochrane Database Syst Rev. 2021 Mar 18;3(3):CD010804. doi: 10.1002/14651858.CD010804.pub3. Cochrane Database Syst Rev. 2021. PMID: 33735441 Free PMC article.
-
Effect of a leucine-rich supplement in combination with nutrition and physical exercise in advanced cancer patients: A randomized controlled intervention trial.Clin Nutr. 2020 Dec;39(12):3637-3644. doi: 10.1016/j.clnu.2020.04.008. Epub 2020 Apr 11. Clin Nutr. 2020. PMID: 32340904 Clinical Trial.
-
A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer.J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):778-788. doi: 10.1002/jcsm.12201. Epub 2017 Jun 14. J Cachexia Sarcopenia Muscle. 2017. PMID: 28614627 Free PMC article. Clinical Trial.
-
The cancer cachexia syndrome.Surg Oncol Clin N Am. 2001 Jan;10(1):109-26. Surg Oncol Clin N Am. 2001. PMID: 11406454 Review.
Cited by
-
Prediction of Treatment Recommendations Via Ensemble Machine Learning Algorithms for Non-Small Cell Lung Cancer Patients in Personalized Medicine.Cancer Inform. 2024 Oct 14;23:11769351241272397. doi: 10.1177/11769351241272397. eCollection 2024. Cancer Inform. 2024. PMID: 39421723 Free PMC article.
-
Harnessing the Systemic Biology of Functional Decline and Cachexia to Inform more Holistic Therapies for Incurable Cancers.Cancers (Basel). 2024 Jan 14;16(2):360. doi: 10.3390/cancers16020360. Cancers (Basel). 2024. PMID: 38254849 Free PMC article. Review.
-
Holistic multimodal care for patients with cancer cachexia and their family caregivers.Asia Pac J Oncol Nurs. 2023 Aug 6;10(Suppl 1):100290. doi: 10.1016/j.apjon.2023.100290. eCollection 2023 Nov. Asia Pac J Oncol Nurs. 2023. PMID: 38197043 Free PMC article. Review.
-
The landscape of immune therapy in vulnerable patients with advanced non-small cell lung cancer: a narrative review.Transl Lung Cancer Res. 2023 Nov 30;12(11):2310-2321. doi: 10.21037/tlcr-23-581. Epub 2023 Nov 21. Transl Lung Cancer Res. 2023. PMID: 38090528 Free PMC article. Review.
-
The Incidence and Management of Cancer-Related Anorexia During Treatment with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors.Cancer Manag Res. 2023 Sep 22;15:1033-1046. doi: 10.2147/CMAR.S417238. eCollection 2023. Cancer Manag Res. 2023. PMID: 37771675 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical